Patient-reported outcomes from a phase HI multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing alter chemotherapy: Cancer Oesophagus Gefitinib (COG)
मुख्य लेखकों: | Dutton, S, Blazeby, J, Petty, R, Mansoor, W, Thompson, J, Harrison, M, Abbas, H, Dahle-Smith, A, Chatterjee, A, Falk, S, Garcia-Alonso, A, Fyfe, D, Hubner, R, Gamble, T, Peachey, L, Harvey, C, Julier, P, Jankowski, J, Midgley, R, Ferry, DR, Grp, C |
---|---|
स्वरूप: | Journal article |
प्रकाशित: |
2013
|
समान संसाधन
-
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
द्वारा: Dutton, S, और अन्य
प्रकाशित: (2014) -
Gefitinib and Epidermal Growth Factor Receptor Gene Copy Number Aberrations in Esophageal Cancer
द्वारा: Petty, R, और अन्य
प्रकाशित: (2017) -
Gefitinib and EGFR gene copy number aberrations in esophageal cancer
द्वारा: Petty, RD, और अन्य
प्रकाशित: (2017) -
Busting the Breast Cancer with AstraZeneca’s Gefitinib
द्वारा: S. Chemmalar, और अन्य
प्रकाशित: (2023-01-01) -
Glycyrol Alone or in Combination with Gefitinib Is Effective against Gefitinib-Resistant HCC827GR Lung Cancer Cells
द्वारा: Shuang Zhao, और अन्य
प्रकाशित: (2021-11-01)